A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Opdualag chalks up another failure, this time in the extension of an approved use.
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
AbbVie follows Gilead in throwing Xilio a lifeline.
